Safety and efficacy pharmacogenetics can be applied successfully to the drug discovery and development pipeline at multiple phases. We review drugtarget screening using high throughput SNP associations with complex diseases testing more than 1 800 candidate targets with approximately 7 000 SNPs. Alzheimer's disease data are provided as an example. The supplementation of target-selected screening with genome-wide SNP association, to also define susceptibility genes and relevant disease pathways for human diseases, is discussed. Applications for determining predictive genetic or genomic profiles, or derived biomarkers, for drug efficacy and safety during clinical development are exemplified by several successful experiments at different phases of development. A Phase I-IIA study of side effects using an oral drug for the treatment of breast cancer is used as an example of early pipeline pharmacogenetics to predict side effects and allow optimization of dosing. References are provided for several other recently published genetic association studies of adverse events during drug development. We illustrate the early identification of gene variant candidates related to efficacy in a Phase IIA obesity drug trial to generate hypotheses for testing in subsequent development. How these genetic data generated in Phase IIA are subsequently incorporated as hypotheses into later Phase clinical protocols is discussed. A Phase IIB clinical trial for Alzheimer's disease is described that exemplifies the major pipeline decision between program attrition and further clinical development. In this case, there was no significant improvement in 511 intention-to-treat patients but, applying a confirmed prognostic biomarker (APOE4) to segment the clinical trial population, all three doses of rosiglitazone demonstrated improvement in patients who did not carry the APOE4 allele. The data for the APOE4 carriers demonstrated no significant improvement but suggested that there may be a need for higher doses. Thus, a development program that would have been terminated progressed to Phase III registration trials based on the results of prospective efficacy pharmacogenetic analyses. The implications of using APOE genotype as a biomarker to predict efficacy and possibly dose, as well as supporting the basic neurobiology and pharmacology that provided the original target validation, is discussed. Citations are provided that support a slow neurotoxic effect over many years of a specific fragment of apoE protein (over-produced by apoE4 substrate compared to apoE3) on mitochondria and the use of rosiglitazone to increase mitochondrial biogenesis and improve glucose utilization. Pharmacogenetics is currently being used across the pipeline to prevent attrition and to create safer and more effective medicines.
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Introduction
The goal of drug development is the registration of a safe and effective medicine. Drug development is a reiterative pipeline process, and success is defined by completing the steps through the pipeline. The application of pharmacogenetics through each step of that process is the focus of this review. To exemplify all the steps between discovery and launch with a single molecule would take 7-12 years, depending on the length of clinical trials for the medical indication. Therefore, we will exemplify each step along the pipeline with a different compound. Most of the current examples in the pharmacogenetic (PGX) literature look at the track records of marketed drugs retrospectively, when the drug and its clinical responses are available to be studied by academic investigators. This review will be divided into experiments representing examples along the successive processes in drug development -with examples from Discovery, Phase I, Phase II and Phase III drug development. 1 The role of genetics will be emphasized, but it is critical to acknowledge that chemistry is the underlying expertise necessary for developing drugs. The role of genetics can be to identify human disease-associated targets, and determine predictors of efficacy and safety. It is also important that the safety process continue post-launch. 2 Safety of marketed drugs is a major health care and legal tort concern. It is more complex than simply stopping access to a drug that has uncommon adverse effects in a small minority of the treated population. An equally important application of safety pharmacogenetics is the effect that withdrawal of medicines from the market has on patients for whom they are effective and safe. When these drugs are withdrawn suddenly, access by well-treated patients is also terminated. This occurs only because a small minority of other patients who could suffer a severe adverse event (AE) cannot be diagnosed/classified/identified before they are treated. If these AE-susceptible patients could be identified before receiving the drug, medical care would be more evidence based and accurate. The increased risks of untreated disease in many patients are frequently forgotten in the headlines. The discussion of this process by the public is usually focused on political 'blame' and legal policies, rather than the delivery of safe medicines to all patients. 3 This review will consider other practical scientific alternatives as part of the drug development and the maintenance of useful therapies.
The topics to be reviewed along the drug development process are particularly applicable to the discovery of relevant genetic classifiers that may be associated with drug responses. These sections include: (1) genome-wide susceptibility gene screening for target and drug discovery based on human disease association studies; (2) when, why and how to use candidate gene panels or whole genome arrays to screen for genetic or pharmacogenetic 'diagnostic' classifiers and their applications to also understand disease susceptibility in the development of specific medicines; (3) applications for pharmacogenetic predictive profiling (efficacy and adverse events) during development; and (4) relationship of APOE alleles found to discriminate clinical efficacy in a clinical trial to an APOE allele-specific mitochondrial mechanism of pathogenesis.
Genome-wide association gene screening for 'susceptibility' or physiologic involvement in disease pathogenesis: Alzheimer's disease example
It is now generally acknowledged that many common diseases are complex with multiple gene variations from several loci acting in concert to produce the clinical expression of a common syndrome. When diseases are classified initially, patients are grouped by having similar symptoms and signs. Complex diseases are usually thought to be the 'same' disease, and then subsequently subdivided by more specific laboratory, imaging or genetic data. Historically, there is a typical initial assumption that the diseases are homogeneous and that their pathogeneses are identical. In fact, these assumptions are almost invariably wrong. It is now possible to simultaneously identify many of the contributing genetic variants for complex diseases using genome-wide single nucleotide polymorphism (SNP) screening. 4 These experiments are strongly dependent on collecting comprehensive information on specific phenotypes (clinical data) for all patients in a particular study. It then becomes possible to group subsets of clinical or phenotypic variants: for example, patients who develop the disease very early in life, compared to the greater population of similarly affected later-onset patients. Palmer and Cardon have recently published a short review of the application of whole genome mapping. 4 Alzheimer's disease (AD) provides a good example of a complex disease with multiple genetic etiologies, including specific sub-types inherited as autosomal dominant traits, as well as common forms related to the inheritance of susceptibility genes. In AD, a recent pharmacogenetic drug development example has progressed successfully from a Phase IIB proof of efficacy study into Phase III. 5 Should Phase III registration studies be successful, then this would be the first drug developed for a complex disease based on susceptibility gene discovery and pharmacogenetic drug response. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] As the description of Professor Alois Alzheimer's first patient in 1907, many clinical distinctions have been made. 15 Yet, as late as 1985, reviews of AD neglected any genetic component. 16 In dementia syndromes of the AD type, it became apparent that there were a small number of families in which patients' signs and symptoms began decades earlier than the common late-onset disease. 11, 17, 18 These uncommon early-onset families were found to inherit familial AD as an autosomal dominant trait. Early genetic linkage studies identified several large sections of the genome (millions of basepairs (bp)), which contained several rare gene variants (mutations) that were identified subsequently. Although the clinical criteria for the diagnosis of AD are the result of expert consensus, deposition of amyloid and plaque formation were anointed as neuro-pathologic diagnostic criteria necessary to confirm the diagnosis of AD -even though there was great variability in the amount of plaque formed. [18] [19] [20] In fact, similar amyloid deposition can be found in many controls with normal cognition. Supporting amyloid as the relevant pathology was the discovery of several very rare, mutations of the amyloid precursor protein (APP, located on chromosome 21) causing autosomal dominant early-onset AD. 6 Other specific APP mutations were found to be associated with cerebral hemorrhage, or no apparent disease. 11 In addition, presenilin mutations, located at two separate loci on Ch 14 and Ch 1, were also 'causal' for early-onset AD, and were subsequently found to be involved with APP metabolism. 7, 8 The inheritance of apolipoprotein E-e4 (APOE4) was found to be highly associated with the density of amyoid deposition as well as genetically associated with common late-onset cases of AD (LOAD). Late-onset cases of AD had been widely considered 'sporadic,' not genetic. 9, 21 Complex genetic diseases were not yet defined by multiple genetic variants at that time. To complicate the dissection of AD, the discovery of mutations of the tau proteins again led to further sub-classification of patients with similar clinical dementias, although this involved patients with more temporoparietal symptoms and signs. [22] [23] [24] [25] [26] [27] Subtle clinical distinctions between these genetic variants were used to narrow the genomic location of mutations or became evident only after the discovery of the linkage regions and/or the mutations.
Point mutation versus common disease pathogenesis
So what is 'AD?' In this field, because all patients with confirmed AD are defined pathologically by amyloid deposition, causal amyloid cascade hypotheses have dominated academic and industry research for more than two decades. 28, 29 The pathogenic processes involved across the various types of AD dementias have significant elements in common, but the relationships between causative genetics and converging pathologic processes needs to be clearly defined if effective disease interventions are to be discovered. Defining the underlying pathogenic processes is important for developing medicines that can change the course of the disease, particularly if the predictive classifiers for response to treatment of each AD sub-type are different.
As will be discussed later in detail, the influence of intraneuronal apoE4 protein metabolism on neuronal vitality and neurodegeneration occurs decades before there is amyloid deposition. This suggests steps in a process, rather than a single genetic hit, with amyloid deposition being a late-occurring manifestation. Perhaps specifc mutations of APP amplify the rate of this process or accelerate a different pathway. The deposition of amyloid as well as many other less celebrated proteins in neuritic plaques may contribute to an increased rate of clinical decline observed as the disease becomes manifest and progresses, but it is certainly not the earliest or only etiology of the long-term pathogenesis. Decreased glucose utilization can be observed before amyloid deposition in engineered transgenic mouse models of amyloid deposition in the brain. 30 Neurofibrillary tangle formation and amyloid-related depositions may have an important role in the autocatalytic rate of disease progression involving several of the genes associated with AD, including APP, presenilin 1, presenilin 2, APOE4, transthyretin, a-macroglobulin, and other to-be-identified contributing gene variants.
Genome-wide screening for susceptibility loci
Having the sequence of the human genome experimentally available now provides scientists the opportunity to perform genome-wide associations in diseases. An expectation is that the multiple contributing loci (as in AD) can be identified simultaneously, and then integrated into pathways contributing to a pathogenetic process for which medicines can be identified. 4, 31 There is now experimental and clinical trial evidence to support this prediction. 5, [32] [33] [34] [35] We have previously described the design of high throughput disease-association SNP studies in type 2 diabetes mellitus (T2DM). 32 This particular SNP screening set was confined to B700 SNP variants of B1800 genes in several drug target classes for which pharmaceutical drug screens were possible to design. This association study was therefore designed as a multiple candidate gene experiment to identify 'drug-able' targets for human disease-relevant drug discovery. Included in the screens were a small proportion of candidate genes that were associated with genetically but not potential chemically tractable targets. These screening experiments were initiated in 2002, before the completion The results from the initial AD screen are particularly remarkable. (Table 1 ) Although false-positives are expected, extensive validation schemes will be used for biological confirmation. However, for the purpose of this review, the major point is that one SNP in one gene had an extremely highly significant P-value even after correction for all 13,101 gene and SNP tests. Once again, APOE4 was confirmed to be associated genetically with AD. Can large-scale genomic screens pick out known disease associations? In this case, if APOE4 is the positive control, the answer is certainly 'yes.' It is also of note that the number of literature-reported associations (which were included in the screens) was much greater than the actual number of confirmed associations that were found in this study. Yet this study was able to also validate several associated genes. In addition, several new genes and pathways of potential interest were identified.
Can other genetic variants, less strongly associated than APOE4, really be identified? While we await the results of the confirmation data analyses and gene-specific validation experiments (total patients 41000, total controls 41000), we have identified significant association signals in several glucose metabolism genes that were previously suggested by proteomic studies to be involved in the pathogenesis of AD. [33] [34] [35] As the candidate selection was biased for genes for which we presumably could screen as drug targets, many metabolic enzymes were not included. However, the scheduled genome-wide analysis to detect regions of linkage disequilibrium that differ in controls and AD patients may point to additional genes not included in the initial large candidate gene experiments. Genome-wide screening can then be applied to both disease susceptibility paradigms as well as drug response analyses, a point to which we will return in the conclusion. Drug responses can be viewed simply as a defined phenotype (AE or efficacy) resulting from the use of an environmental agent -the drug.
Using proteomic data for metabolic pathway analysis in Alzheimer's disease Previous proteomic data from APOE knock-out and humanized transgenic APOE mice had suggested that glucose metabolic processes were affected differentially in these animals (and confirmed by human positron emission tomography (PET) studies). [36] [37] [38] [39] [40] [41] How does the absence of an APOE gene lead to decreased glucose utilization? The metabolism of glucose and oxygen is primarily the function of mitochondria in eucaryotic organisms. [42] [43] [44] Studies of the glucose metabolic enzymes over-or under-expressed in brains from APOE knockout mice compared to wild-type mice first suggested that this process may be an early and fundamental process affected in human APOE4 carriers. 33, 35 Interference with the generation and/or storage of energy in cells, particularly in well-differentiated neurons lacking mobility, could be a lifelong circumstance leading to gradual strangulation of neuronal structural plasticity, dendritic communications, and structural stability. 45 How does the metabolism of apoE variants affect neuronal metabolism over long periods of time, differentially resulting in neurodegeneration? Does APOE4 or its metabolites preferentially target neurons in brain regions particularly associated with AD? Are other neuronal cell populations in other neurodegenerative diseases where regional glucose utilization is impaired targeted by genetic variants of other genes? These questions will be addressed later in this review.
How, why and when to use candidate gene strategies versus genome-wide screening for drug development Identification of drug classifiers for drug development How often will an analysis of polymorphisms from molecules with some disease-related metabolism provide informative data for association studies? Goldstein et al. 46 have stated in a recent review of drug responses from marketed medicines that '42 polymorphisms that have been significantly associated with drug response in at least two studies show that obvious candidate genes, such as drug-metabolizing enzymes and drug targets, often carry important pharmacogenetic polymorphisms, and that such polymorphisms are often owing to common alleles.' Our data would agree with those views in that marker associations have been developed in several Phase IIA development pipeline experiments that are related to candidates derived from the known or suspected mechanism of action of the drug in the trial. Potential efficacy classifiers or markers developed using the post hoc analyses from the already completed trial can then be confirmed in subsequent clinical trials. 1 Practically, it is assumed that the initial evaluations will be performed with mechanism-directed candidate gene sets before more complex and expensive genome-wide studies would be initiated. Sequential analyses in subsequent clinical trials along with genomic and proteomic validation experiments serve to confirm real associations and eliminate false-positives.
Oncology represents a special case where classifiers are derived from cancer biopsy tissue, which is often available for generating potential genetic and genomic markers. Oncology genomic classifiers have been reviewed recently in this Journal. 47 The take-home message is that investigators of other complex diseases do not have readily available biopsy tissue for transcriptomic or proteomic studies. Thus, most complex diseases are experimentally distinct from oncology examples in discovering marker panels for measuring responses to drugs. In oncology, newer methods of genome-wide SNP microarrays are now available to examine genetic recombinations as well, including chromosomal break points, duplications, deletions, etc. It will become relatively routine to study drug responses by tumors based on genetic and genomic data by comparing successive tumor samples. 48 Figure 1a and b illustrate tumor data from one biopsy characterized by using the 100k marker Affymetrix Centurian chip. Analyses of common deletions, duplications, and genetic SNP associations may allow patients to be selected for therapies based on their predicted treatment response to the drug in early clinical trials. 49 Unfortunately, oncology is a special field; most complex human diseases do not have biopsy tissues readily available for similar transcriptomic or proteomic analyses. Adverse event PGX represents a separate, distinct problem. After dosage with a drug, patients with a specific clinical complication or AE suddenly appear from a treatment group of clinically defined disease. This is a different paradigm from studying susceptibility gene variants for a clinically-defined disease which, as described above, involves hundreds to thousands of well-defined patients in multiple clinical trials for statistical confirmation. 1, 49 Very few patients with severe AEs, in a clinical trial can be tolerated, so that the fundamental search for PGX AE classifiers for these patients must necessarily involve fewer patients, but the classifier information can be derived from the whole genome. This paradigm involves, therefore, a comparison of a few patients identified by the occurrence of a special unwanted phenotype compared to many patients who have not suffered the AE. One might assume that the comparison group might also have had to be treated with the drug, but if the event is uncommon, large ethnic-specific control databases of 1000-3000 subjects will be useful. 1 For the purpose of genome-wide pharmacogenetic analyses for AEs, where individualized predictive data are necessary, allele frequency variations between ethnic groups may be far greater than the variant associated with the AE phenotype. Therefore, controlling for specific ethnic variations may control the 'noise' of patient heterogeneity and be the most practical consideration for analyzing uncommon AEs. An example of how few patients could be needed to identify a classifier was initially reported in 2004, and has been confirmed in several other clinical situations. 1, 50, 51 As a note of interest, classifier studies of severe rare AEs resulting from many different drugs, such as long QT and StevensJohnson syndrome, can be performed using relatively small but rigorously phenotyped subsets of patients.
The use of ethnic-specific genetic data is generally applied to evolutionary, population, and other medical applications. It is particularly useful for defining genetic classifiers of drug responses using a standardized PGX methodology. 1,2,49 As 
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Figure 2 Phase IIA Proof of Concept efficacy study of a drug for obesity. This figure illustrates the results of a Phase IIA efficacy clinical trial of a molecule intended for the treatment of obesity. The graph shows weight change in the 40 drug treated patients (purple line) compared to 41 placebo treated patients (blue line) during the duration of the 2 month double blind trial. There are a significant proportion of drug-treated patients with weight loss 41.7% , with an obvious hyper-responder group with a patient as high as 9%. Two SNP polymorphisms related to the proposed mechanism of this molecule and one SNP related to a related hypothesis concerning obesity segregated as homozygous with the hyper-responders. Each was homozygous for a single allele (labeled 2/2) with the other allele homozygotes concentrated on the left side of the curve (1/1). Heterozygous patients (1/2) were clustered in the middle. In this experiment, treated patients with the 2-2 genotype for any of the three SNPs averaged 43.3 kg weight loss, while trial participants with the 1-1 genotype averaged 41.3 kg weight gain. This pattern suggests that an intent to treat responder group might be enriched in subsequent Phase IIB trials if patients who are 1/1 homozygotes were excluded. This hypothesis is currently being confirmed in larger, ongoing dose-finding studies.
we are currently using these PGX methods throughout drug development of medicines targeting diverse populations, GSK has decided to place several ethnic control series of 1000-3000 individuals with genome-wide screening data into the public domain on the appropriate public websites. Thus, medical investigators with access to patient resources will be able to incorporate these ethnic-specific SNP control databases for their own experiments (rather than only being possible in 'big' laboratories), assisting a wide breadth of academic investigations for which a relatively small number of suitably phenotyped patients are available for research. The commercial imperative is to provide the pharmaceutical regulatory agencies, such as FDA, EMEA and PMDA (Japan) with the control data necessary for their statisticians to be able to confirm our (and presumably other pharmaceutical companies') PGX-based data submissions. 52 The major differences in the application of either candidate gene sets or genome-wide screen technologies are determined by whether they are 'fit for purpose.' In applying PGX across the pharmaceutical pipeline, the limitations are defined by the relatively small number of patients in whom AEs can be tolerated. For efficacy PGX, clinical trial populations are being segmented for efficacy in sequential, hypothesis-generating, and hypothesis-confirming clinical trials. In the efficacy case, early Phase IIA studies may provide initial candidate variant hypotheses associated with efficacy. These hypotheses can be included in subsequent clinical trial protocols so that they can be confirmed and validated as a drug progresses through the pipeline. As the drug progresses, larger numbers of patients are analyzed in Phase IIB and Phase III. The only way to generate and confirm associated genetic markers is to generate and test each hypothesis during the conduct of sequential clinical trials, an activity that is centered predominantly in pharmaceutical companies and is difficult to manage in academic environments.
There is a well-developed knowledge base concerning the major drug-metabolizing enzymes. [52] [53] [54] [55] Variations in the sequences of these metabolizing genes can illustrate how efficacy may be increased by understanding the proper dosing of individuals. In fact, it is also possible to use a similar analysis to develop classifiers of adverse side effects in early drug development. (See Phase I-IIA optimization of dosing for efficacy.)
Applications for determining PGXs predictive profiles (efficacy and adverse events) during development Phase I-IIA optimization of dosing for efficacy One of the most important aspects of drug development is getting the dose right. The first consideration is usually efficacy, as severe safety signals early in development lead directly to attrition. Using individualized dosing information, it is also possible to maximize the effective dose for segments of the patient populations without compromising safety. Kirchheiner et al. 56 modeled drug dosing based on a range of pharmacogenetic examples involving CYP2D6 metabolizers. They demonstrated how drug exposure can be classified within a fourfold range in dose options within the treated population. This should be compared to the current prevalent method of establishing a toxic level and then dosing everyone with less than that dose. There will be some individuals for whom the 'toxic' level may not be toxic due to their increased rate of drug metabolism. In these patients, it is possible to achieve a higher rate of efficacy using higher doses. Kirchheiner et al. considered a 'standard' indicated dose to be 100 U. Dose-ranging studies based on CYP2D6 variants for a number of drugs would define: poor metabolizers (7% of the Caucasian population) 60 U, intermediate metabolizers (40%) 80 U, extensive metabolizers (50%) 160 U and ultra-rapid metabolizers (24%) 240 U. This simulation demonstrates that the standard prescribed dose for an asset metabolized by CYP2D6 overcompensates for the fewer poor metabolizers. As a result a majority of the population that was modeled would receive a lower dose than indicated by their individual capacities to metabolize the drug. The majority of patients are actually receiving a sub-optimal dose for efficacy when their treatment is based on the empirical risk of overexposure for poor metabolizers. Routine testing for classifiers of drug response would allow optimal dosing for efficacy for more patients who are just as deserving of safe and effective medications as the fewer poor metabolizers. 56 In fact, the current situation can contribute to increasing AEs in the relatively poor metabolizers and lack of efficacy in many patients who could tolerate higher doses safely and benefit from the drug.
Phase I-IIA dosing based on early adverse events: mild side effects in a small number of individuals classified during very early drug development In classical genetic disease studies, if the gene responsible for an inherited disease is known, it is usually sufficient to screen a single patient with all the variants/mutations associated with the disease to discover the exact mutation. Thus, a patient suspected of having cystic fibrosis can be screened for all the known mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene and most likely be diagnosed at a DNA level. For small numbers of patients in early drug trials (i.e., less than 10-20) suffering particular AE phenotypes, the use of high-density SNPs from candidate gene analyses can be very effective, while genome-wide linkage disequilibrium screening against a large panel of ethnicity-matched controls would be less useful. Usually, when the molecule has reached First Time in Human (FTIH) studies, a considerable body of information regarding the mode of action, receptors, other biology and metabolism has been collected and hypotheses around candidate genes can be generated. If that SNP coverage for each gene can be generated (or may exist already in a commercial format), each gene can be evaluated for genetic associations (including linkage disequilibrium mapping).
Candidate molecules are first tested for safety in generally healthy volunteers without the disease. These subjects are followed very carefully in clinical research units. In the case of 107 normal healthy subjects and affected oncology patients initially exposed to Tykerb (a dual kinase inhibitor in clinical trials as a cancer therapy) in Phase I and early Phase IIA trials, 18 people suffered from diarrhea or skin rash, or both. A PGX analysis of this group of volunteers and patients exposed to the drug started with a relatively dense array of polymorphisms from five candidate enzymes already known to be involved in the metabolism of Tykerb.
57 Table 2 lists the metabolizing genes, the number of polymorphic markers tested from each gene, and the distribution of the markers across the genetic locus.
The results were informative. Statistically significant associations were observed between 34 SNPs in CYP2C19 and rash (20, Po0.01), diarrhea (four, Po0.01) and T max (10, Po0.01), and between 14 SNPs in ABCB1 and T max (Po0.01). Notably, all three subjects (two healthy volunteers, one patient) homozygous for the CYP2C19*2 allele experienced both mild rash and severe diarrhea. (CYP2C19*2 was associated with diarrhea at Po0.001, CYP2C19*2 was also associated with rash at Po0.005). These data show that it is possible to determine pharmacogenetic associations to side effect phenotypes during the earliest phase of clinical drug development. These results are currently being validated in a larger cohort of patients from ongoing phase II and III Tykerb clinical trials. Overall, rash and diarrhea have occurred infrequently in clinical trials with Tykerb and are generally mild. These data will be used with data from subsequent trials to understand a genetic basis for dosing to avoid side-effects. 56 Cancer therapies usually make use of multiple drugs. Understanding the pharmacogenetic associations with each may also help determine mechanisms of drug toxicity and may have important implications for designing combinations with other agents. In fact, combination drug therapies can be similarly analyzed.
Efficacy example with relative small numbers of non-metabolising candidate SNPs to generate efficacy classifiers We previously published an example of efficacy pharmacogenetics with one of the easiest phenotypes to illustrate loss or gain of weight in an obesity Phase IIA clinical trial ( Figure  2 , reference Roses 1 ). In this study, in which 81 patients provided informed consent and DNA, there is a relatively clear sub-group of 40 treated patients on the right side who received the drug, who lost more weight than those in the placebo group. On the left side of the figure are the patients who gained weight. If a patient gained weight, they were more likely to be in the placebo group. Thus two separate clinical indications for potential treatment are suggested. The first for weight loss, and the second to avoid gaining weight.
The question for this review is how can we develop early genetic markers that may be predictably associated with either weight loss or weight gain. One hypothesis is that patients carrying homozygous SNP alleles are distributed to the far left and the far right, depending on relative allele frequencies. Heterozygous patients occupy the middle. To detect this genetic allelic separation, a panel of candidate genes was constructed involving the target, the molecule, what was known about the molecule's metabolism, hypotheses about obesity. Multiple SNPs from each candidate gene were screened looking for predominant homozygosity on the far right (labeled '2-2') with the distribution of any '1-1' homozygous patients on the far left of the curves. Three markers from three mechanism-related genes segregated across the tested populations in that fashion.
These three markers were defined 'post hoc' in a small experiment and can only be considered for hypothesis testing in the next larger Phase IIB clinical trial. If one or more of these three classifiers (or one of several others of potential interest) are confirmed in a larger trial, then there will be continuing opportunities to provide further confirmations in Phase III trials. In addition, there could presumably be information generated that may illuminate a previously unrecognized aspect of the mechanism of action of the drug. An example of a confirmed biomarker being tested in a Phase IIB clinical trial is discussed below (see Rosiglitazone and AD in the subsequent section).
The regulatory environment for analyzing PGX data Regulatory agencies, particularly the FDA in the US, have led the way in trying to understand how genetic and genomic 'biomarkers' can be developed and used for selection of patients to provide a greater probability that the patients will respond favorably. 52 Publication of the Critical Path Innovation/Stagnation document (http://www.fda.gov/oc/initiatives/criticalpath/whitepaper. html) and Guidance for the Submission of Genomic Data (www.fda.gov/cber/gdlns/pharmdtasub.pdf) has provided an opportunity for discussion of genomic data before a regulatory decision, enabling both the sponsors and the Agency to be educated. The agencies are provided with an early view of genomic experiments and suggestions of how the data might be used in product registration. The sponsors have an opportunity to discuss their new ideas and receive advice and discussion in a non-decision making, informational meeting. A discussion called 'Voluntary Genomic Data Submission' (http://www.fda.gov/cder/genomics/ VGDS.htm) has been quite effective for communicating genomic strategies and data. Similar meetings have also been initiated by other regulatory agencies, including the EMEA and PMDA. 52 There are, however, some general principles concerning the use of data obtained in the context of a clinical trial, which remain unchanged by genomic applications. The primary and secondary end points for each clinical trial must be clear and validated. Thus, the generation of classifier data in a particular study provides only a 'post hoc' analysis, and the data analyses must be incorporated into the protocols to be tested in subsequent trials. This progression of data from post hoc, through pre-specified in the next protocol, through prospectively re-confirmed studies defines the process to apply new genetic biomarkers to predict efficacy during drug development. A single analysis from an early trial will not be sufficient to declare a biomarker validated as a DNA (or RNA) variant classifier.
Progression of tests in ensuing validation studies will weed out false positives. PGX classifier discovery must be viewed across the Drug Development pipeline with the same forward thinking as chemical leads move through the candidate stage into proof of concept in Drug Discovery. Regulatory Guidance is being developed so that the drug and its 'diagnostic' (or 'classifier') may be launched together. A situation where a validated biomarker for a disease already exists will be quite distinct from the process of validating newly developed DNA profiles for efficacy.
Differentiation of rosiglitazone-treated AD patients by APOE genotyping: an example of an established validated biomarker for Phase IIB efficacy PGX
There is a large literature confirming APOE as a biomarker associated with allele-specific age of onset distributions of common, late-onset AD. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] As will be discussed later, there are also many studies which independently developed a rationale for glucose-utilization differences in the nervous system of patients with AD and other neurological syndromes related to recovery of brain function after stress (e.g. recovery from stroke, post-traumatic concussion, multiple sclerosis). The well-documented association of the APOE4 variant with risk for AD was reconfirmed in our diseaseassociation candidate gene study (Table 1) . Although APOE does not represent a drug target that is amenable to the types of high-throughput chemical assays currently used in the pharmaceutical industry, it and other proposed candidate genes had been added to the genetic screen. When a new association is found but the molecule is not suitable for direct chemical screening, placing it in the context of related cellular pathways may suggest more drugable targets. In 2006, pathway analyses of genetically associated genes are performed routinely using increasingly sophisticated bioinformatic systems with active literature searches.
When clinical trials for a potential drug molecule proceed, it is reasonable to nominate associated candidate biomarkers selected from pathway analyses or prior genetic association studies. APOE4 was validated using clinical epidemiology and age of onset studies. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] We selected the presence or absence of the APOE4 allele with the hypothesis that different APOE alleles may be related to the drug response of patients with AD. Thus, sub-group analyses using APOE4 carrier status was proposed in the clinical trial protocol prospectively, before the clinical trial was started. 5 In a Phase IIB clinical trial of rosiglitazone in mild to moderate AD, the initial analyses were performed in the whole Intention to Treat (ITT) population. 5 The clinical trial was designed as a 24-week monotherapy trial with the primary endpoint being improvement of the ADAS-cog scores. We were surprised and disappointed with the initial analyses in the ITT population of 511 patients to determine that no significant clinical effect was observed. (Figure 3a) Using the biomarker proposed in the clinical trial protocol, APOE4 carrier status, the patient population could subsequently be segregated to examine therapeutic response. The data were striking. AD patients without an APOE4 allele responded to all three doses of rosiglitazone while those patients who carried an APOE4 allele did not respond at the lowest dose, but had greater responses at the two higher doses (Figure 3b) . It was also noted in this particular study that the APOE4 carrier placebo population, which was deteriorating as expected at week 16 improved at week 24, was not behaving as would be expected in untreated patients, and thus constituted an uninterpretable single experiment. The environmental agent being tested for clinical response is the drug. The pharmacogenetic analyses compares only the rosiglitazone-treated patients who were Mean change from baseline to in ADAS-Cog total scores in APOE 4-negative patients was significant (P ¼ 0.014). Subsequent exploratory testing revealed that APOE 4-negative patients, after 24 weeks, showed a general trend of improvement in cognitive function as a result of treatment with rosiglitazone. This improvement was nominally statistically significant at the highest 8 mg rosiglitazone dosage compared to placebo (P ¼ 0.024). APOE 4-positive patients did not show an improvement in cognition compared to the implausibly improved placebo response in the APOE 4-positive group. However, there may be a dose effect on treatment in APOE 4-positive patients, with 2 mg having no effect (overlaps the in APOE 4-negative placebo). A positive effect of 4 and 8 mg doses may be another interpretation of these data. These uncertainties will be more fully studied in larger Phase III clinical trials.
Complex disease-associated pharmacogenetics AD Roses et al selected by their biomarker, i.e., þ /À APOE4 differentiated efficacy responses. Subsequent clinical trials will incorporate additional hypotheses based on APOE genotypes, and there will be ample opportunities in larger and longer studies to re-test and assess the believed-to-be spurious 24-week APOE4 þ placebo point. As stated above, a major benefit of testing efficacy PGX in the context of early pharmaceutical development is the assumption that additional data will be collected from sufficient numbers of patients to support registration. The complete clinical trial results relative to all the primary and secondary clinical end points are being prepared for publication.
Actually, several different interpretations could be discussed with the regulators in a Voluntary Genomic Data Submission (VGDS) meeting. The first is that the 24-week APOE4 þ placebo point is not interpretable and the experiment must be repeated with no interpretation of benefit to APOE4 carrier patients. The second is far more interesting and provides possible insights for the design of subsequent clinical trials. If the responses of the drug-treated patients are taken alone (as is the case definition in PGX studies which involve treatment with a drug), then the initial data for APOE4 carrier analysis suggest that the 2-mg dose was ineffective, but there was some improvement with the 4-and 8-mg doses, although not to the extent as observed in APOE4 non-carrier treated patients. (Figure 3b) The beauty of the next experiment is that it can be designed prospectively and, with minimal delay, be incorporated into subsequent clinical trial studies. It is also encouraging that the latter interpretation fits the current hypothesis for AD pathogenesis, that apoE4 protein and its C-terminal degradation product have a greater effect of inhibiting mitochondrial function than observed with apoE3 (to be reviewed below).
Relationship of the APOE4 allele association and measures of clinical improvement to APOE allelespecific mitochondrial mechanism of pathogenesis Mahley et al. 58 have recently reviewed the critical functions of apoE4 protein in neurodegeneration and the physiological responses of the CNS to stress and injury. In this section, several distinct topics will be summarized. The first involves an understanding of the role of apoE in neurobiology, including sites of synthesis in the CNS. In addition, the unique structural feature characteristic of apoE4 that distinguishes it from apoE3 (and apoE2) and that leads to the detrimental effect of apoE4 will be discussed. The second section describes the neuropathological consequences of apoE synthesis by neurons that are associated with the generation of bioactive fragments of apoE (E44E34E2) that disrupt mitochondrial metabolism and dynamics and lead to neurodegeneration. The third section will describe the experimental support for rosiglitazone in neuronal mitochondrial proliferation, increasing gene expression of mitochondrial-based pathways, and potential therapeutic implications for AD and other neurological diseases.
Role of apoE in neurobiology
ApoE functions as a lipid transport protein in the nervous system and plays a fundamental role in the maintenance and repair of neurons; however, the isoforms differ in their ability to perform these functions. [58] [59] [60] [61] [62] Although the three common isoforms (apoE2, apoE3 and apoE4) differ only by a single amino-acid interchange at residue 112 or 158, these differences profoundly alter their structures and function. ApoE3, the common isoform, has Cys-112 and Arg-158 whereas apoE4 has Arg at 112 and 158 and apoE2 has Cys at 112 and 158.
It is well documented that apoE4 is involved in neuropathology in a variety of disorders, [63] [64] [65] [66] [67] [68] [69] [70] [71] especially AD. [10] [11] [12] [13] Emerging data indicate that there are multiple pathways whereby apoE4 can lead to neuropathology depending on its cellular origin, the nature of various injurious stressors on the CNS, and the unique structural features of apoE4. ApoE4 sets the stage for neurodegeneration. It is envisioned that apoE4 acts in concert with various 'second hits' that are injurious to the CNS or act as 'stressors.' The second hits may be genetic, for example, APP mutations; metabolic, for example, ischemia, oxidative stress, insulin resistance; or environmental, for example, aging, head trauma, or infectious agents. Understanding the complexity of the neurodegenerative processes involving apoE4 can lead to numerous therapeutic approaches for the future.
Sites of synthesis and differential intracellular metabolism
The brain is the second largest producer of apoE, 59, 72 with astrocytes responsible for most of the synthesis in normal brain. 71, 73 However, it is now clearly established that neurons, especially in the hippocampus, can be induced to express apoE under a variety of pathophysiological conditions, including aging, ischemia, trauma, excess Ab production, oxidative stress, and other injurious factors ( [74] [75] [76] , for reviews see Mahley et al. 58 and Huang et al. 62 ). Over the years, we have hypothesized that expression of apoE is induced to protect or repair and remodel injured neurons, processes that occur throughout life. However, apoE4 appears to be less effective than either apoE3 or apoE2 in these processes. More importantly, neuronal apoE4 synthesis is detrimental because during transit through the secretory pathway it undergoes proteolysis, generating neurotoxic fragments. 58, 62 ApoE4 is the most susceptible isoform to this proteolysis (E44E34E2), resulting in the generation of carboxyl-terminal-truncated fragments that enter the cytosol and interact with the cytoskeleton and mitochondria (see discussion to follow).
Unique structure of apoE4
The apoE isoform-specific effects in neurobiology arise from the structural differences among the isoforms. 58, 61, 62 Arg-112 in apoE4 has a profound effect on its structure, resulting in a unique property referred to as domain interaction. [77] [78] [79] [80] Domain interaction was postulated to underlie the association of apoE4 with AD. 78 X-ray crystallographic studies of apoE4, apoE3, and apoE2 demonstrated that in the presence of Arg-112 in apoE4, the side chain of Arg-61 extends away
Complex disease-associated pharmacogenetics AD Roses et al from the 4-helix bundle that characterizes the aminoterminal domain and is available to interact with Glu-255 in the carboxyl-terminal domain through a putative salt bridge. On the other hand, the side chain of Arg-61 in apoE3 and apoE2 is buried between two helices of the bundle and less available for interaction with Glu-255. Thus, apoE2 and E3 are less likely to undergo domain interaction.
Mutation of either Arg-61 to Thr or Glu-255 to Ala abolishes domain interaction and converts the apoE4 to an apoE3-like molecule functionally. This was shown using a lipid-binding assay in which it was demonstrated that apoE4 has a preference for larger, triglyceride-rich lipoproteins, whereas apoE3 has a preference for small, phospholipid-rich particles. 78 With apoE4 in which domain interaction has been abolished by mutation of Arg-61 or Glu-255, the apoE4 mutant switches from a preference for large particles to small particles resembling the apoE3 preference. In addition, we have also identified small molecules that block domain interaction in apoE4 and used these compounds in cellbased assays to demonstrate the effects of domain interaction. 81 For example, we demonstrated that apoE4 stimulated Ab production in cultured neurons to a greater extent than apoE3, and the small molecules abolished the apoE4 induction of Ab production by eliminating domain interaction, converted apoE4 to an apoE3-like functional molecule.
Domain interaction was also introduced into a mouse model. Mouse apoE, which lacks Arg-61 (contains Thr at this site) but contains the equivalent of Arg-112 and Glu-255, does not display domain interaction. However, mouse apoE can be converted from an apoE3-like form to an apoE4-like functional molecule by introducing Arg-61 by gene-targeting. The mouse 'Arg-61' apoE displayed a preference for the large, triglyceride-rich lipoproteins, whereas wild-type mouse apoE behaves like human apoE3 with a preference for small, phospholipid-rich lipoproteins.
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ApoE4 domain interaction was demonstrated by fluorescence resonance energy transfer (FRET) in Neuro-2a cell-culture studies. 83 When apoE3 or apoE4 constructs containing the yellow fluorescent protein at the amino terminus and the cyan fluorescent protein at the carboxyl terminus were transfected into Neuro-2a cells, apoE4 gave a FRET signal demonstrating that the amino-and carboxylterminal domains of apoE4 were in close proximity (o100 Å ). At comparable expression levels, intracellular apoE3 gave a much lower signal, as did the apoE4 Arg-61-Thr or Glu-255-Ala mutants in which the FRET signal was decreased to apoE3 level in the cells. Likewise, the two domains were demonstrated to be closer together in apoE4 than in apoE3 in vitro using FRET and electron paramagnetic resonance spectroscopic measurements of the exact distances between the two domains. 84 A critical role for domain interaction on the functions of apoE has not only been shown with respect to a lipoprotein binding preference 78 and reducing apoE4-induced Ab production 81 but also in apoE4 potentiation of Ab-induced lysosomal leakage and apoptosis in neurons (unpublished) and in apoE4 susceptibility to neuronal proteolysis (see below). Based on the demonstrated effects of domain interaction in apoE4, it is envisioned that inhibiting domain interaction by small molecules may represent a new therapeutic approach.
Effects of ApoE4 and its fragments on mitochondrial integrity and function Impaired calcium homeostasis [85] [86] [87] [88] [89] and decreased glucose metabolism, [34] [35] [36] [37] [38] [39] reflecting mitochondrial dysfunction, might represent early neuropathophysiological changes in AD. In both AD patients and age-matched nondemented subjects, apoE4 is associated with decreased cerebral glucose metabolism. [36] [37] [38] [39] [40] [41] [90] [91] [92] [93] [94] [95] Importantly, apoE4's effect on cerebral glucose metabolism occurs decades before cognitive impairment [36] [37] [38] and, probably, also before significant Ab deposition, implying a causative effect of apoE4 on mitochondrial dysfunction early in life. Mitochondrial dysfunction is clearly coupled with production of reactive oxygen species and increased oxidative damage, which, in turn, further impairs mitochondrial activity. [96] [97] [98] [99] [100] [101] Temporary or sustained loss of mitochondrial function impacts cellular defenses and repair mechanisms, resulting in a decreased capacity of neurons to mount an appropriate stress response and causing cellular injury.
Recent studies from Gladstone provide insights into the molecular and cellular mechanisms underlying apoE4's effects on mitochondrial integrity and function. 102 Coupled with the demonstration that neurons do synthesize apoE under diverse pathophysiological conditions (e.g., aging, Ab toxicity, brain trauma, oxidative stress and ischemia), 58, 62, 103, 104 apoE4 undergoes proteolytic cleavage generating carboxyl-terminal-truncated fragments that enter the cytosol and cause neurodegeneration and behavioral deficits in transgenic mice. [105] [106] [107] One target of these fragments are neuronal mitochondria. 108 The fragments of apoE are much more prominent in the brains of AD patients than in age-and sex-matched controls and in the brains of neuron-specific enolase-APOE4 transgenic mice. 106, 107 ApoE4 protein is more susceptible to cleavage than apoE3 or apoE2 proteins. The fragments escape the secretory pathway and translocate to the cytosol where they interact with cytoskeletal elements, stimulating tau phosphorylation and neurofilament inclusions, and interact with mitochondria, leading to mitochondrial dysfunction and neurotoxicity. 105, 108 Importantly, the receptor-binding region (amino acids 135-150) of apoE is required for escape from the secretory pathway, and the lipid-binding region (amino acids 241-272) is required for mitochondrial interaction. 108 It appears that positively charged amino acids in the receptor-binding region, a feature shared among the protein translocation domains of many viral proteins, 109, 110 enable apoE4 fragments to translocate across membrane compartments of the secretory pathway and enter the cytosol, whereas the lipid-binding region interacts directly with the mitochondrial membrane. 108 Interestingly, almost 20 years ago, Gladstone studies revealed that apoE avidly bound to mitochondrial ATPase. 111, 112 In addition, low levels of apoE have been identified in hepatocyte and neuronal mitochondria.
The enhanced susceptibility of apoE4 to proteolytic cleavage in neurons results from domain interaction (unpublished). Importantly, the apoE4 domain interaction that occurs in neuronal cells 83 is associated with increased proteolytic cleavage. The susceptibility of apoE4 to proteolytic cleavage is markedly decreased when domain interaction is abolished by mutating Arg-61 to Thr or Glu-255 to Ala (unpublished).
Time-lapse recording microscopy of cultured neuronal cells demonstrates that apoE decreases mitochondrial mobility in an isoform-specific manner (apoE4 fragment4apoE44apoE3) (Brodbeck J, Mahley RW, and Huang Y, unpublished observations). Likewise, apoE4 impairs axonal transport of mitochondria in transgenic mice with neuron-specific expression of apoE4. 114 Disruption of mitochondrial transport in neurons may contribute to AD pathology. [115] [116] [117] [118] Moreover, regulation of mitochondrial distribution is essential for generating and maintaining distinct axonal and dendritic domains in response to local metabolic demand, morphological plasticity and memory formation. [96] [97] [98] [99] [100] Failure to deliver mitochondria to appropriate sites results in energy starvation, local disruption of calcium homeostasis, and impairment of synapse formation. 97, 101, 119 Importantly, apoE3 also undergoes proteolytic cleavage, albeit to a lesser extent than apoE4. [105] [106] [107] Thus, apoE3 fragments might also contribute to the development of AD in apoE3 carriers, which is consistent with the different effects of apoE3 and apoE4 on AD age of onset. The possibility that rosiglitazone increases mitochondrial number or function as the underlying mechanism for cognitive decline in AD patients (see below) suggests that the detrimental effects of apoE fragments on neurons may be overcome by 'mitochondrial protectors'. 5, 58, 102, 108 In addition, blocking apoE cleavage by a protease inhibitor may represent an effective combination therapy. 58, 62, 102, 104 Rosiglitazone effects on glucose-stimulated thermogenesis increasing mitochondrial prolifereation and increasing metabolic capacity A perspective on the contributions of target validation experiments, effects of pharmacologic agents (PPARg agonists) on glucose metabolism in transgenic APOE isoformspecific animal models and the effects of rosiglitazone on mitochondrial metabolism and mitogenesis was recently published. 35 Metabolic studies of the effects of rosiglitazone in patients with T2DM also support the notion that similar cellular processes occur in neurons, leading to specific forms and topography of neurodegeneration. 120 Briefly reviewed below are data from both T2DM mouse models and human T2DM patients which demonstrate a similar effect of rosiglitazone in adipocytes and other relevant tissues. Cells from these tissues have an advantage over the relatively fixed morphology of the neurons in the CNS. Neuronal cells have a limited repertoire in their responses, essentially limited local plasticity, internal cellular dynamic responses, or gradual degenerative prosesses. The maintanence of the intracellular environment is highly dependent on energy production from glucose metabolism (including lactate), without stores of other substitute fuels.
Effects of PPARg agonists on glucose metabolism in T2DM
There is a growing body of evidence supporting mitochondrial dysfunction in T2DM. 120 Mitochondrial dysfunction has been implicated in the pathogenesis of several neurological diseases, including AD, Parkinson's disease, deafness, progressive supernuclear, palsy, schizophrenia, motor neuron diseases and others. [121] [122] [123] [124] [125] [126] [127] [128] These effects of rosiglitazone on mitochondria metabolism may be in addition to its known insulin-sensitization effect. In fact, the mitochondrial responses may actually be part of that mechanism. 129 Oxidative products from glycolysis and b-oxidation of lipids converge in the mitochondria. Further oxidation of these metabolites drive oxidative phosphorylation and synthesis of ATP. These processes are essential for energy metabolism of eucaryotic cells. 130 Rosiglitazone and PPARg agonism induce mitochondrial biogenesis as well as oxidative metabolism in mouse adipocytes. 131, 132 Decreases in mitochondrial number, size, and oxidative capacity are associated with T2DM and obesity. 133, 134 Thus, there appear to be similar metabolic features in several diseases. There have been recent suggestions that there are epidemiological relationships between T2DM and AD. 135, 136 A recent pharmacoepidemiological study specifically studied the incidence of AD in patients with T2DM who were treated with thiazolidinediones (TZDs were either rosiglitazone or piaglitazone). In a retrospective study of approximately 142 000 veterans, Miller et al. reported that the rates of AD were lower in TZD initiators regardless of subsequent use of insulin or other diabetes drugs, and it was found by Ryan et pretation that rosiglitazone can modify the progression of AD in T2DM patients not selected by genotype. Further prospective studies may well find an APOE isoform-specific association as well.
Effects of rosiglitazone on mitochondrial biogenesis Strum et al. 138 found that rosiglitazone stimulated mitochondrial biogenesis in mouse brain in an APOE isoformspecific manner. They used mice that had the native APOE gene knocked-out and mouse APOE was replaced by transgenic human APOE isoforms. The number of mitochondria was quantitated by calculating the ratio of a mitochondrial-derived gene and a nuclear-specific gene (Figure 4 ) (Figure 8 in reference 35 ). Gibson et al. had previously reported that mitochondria from postmortem AD brains were more dysfunctional in tricarboxylic acid cycle enzymes when the APOE4 allele had been inherited. 126, 127 Increased numbers of mitochondria in the APOE4-transgenic mice may be an adaptive response to the presence of human apoE4 protein that maintains total cellular mitochondrial levels sufficient to allow survival. Based on an extensive series of studies in APOE isoform-specific transgenic mice, Strum et al. proposed that 'rosiglitazone agonism induces neuronal mitogenesis and glucose utilization leading to improved cellular function.' 35, 138 This provides experimental support for the hypothesis that mitochondrial dysfunction is the seminal process in the pathogenesis of AD.
Generation of a mitochondrial hypothesis for AD and other neurodegenerative diseases
Little is newly discovered in science. Ideas and unappreciated data frequently already exist in the literature. The critical element is the linkage of unconnected facts into a coherent hypothesis to be tested. In the case of rosiglitazone and AD, linking the apoE4-specific association with disease and a new method of treatment based on that hypothesis is what is compelling. The study of disease-association genetics led to the identification of APOE4 as a major susceptibility factor in AD; an association that was unknown and unsuspected in 1992. 9, [11] [12] [13] [14] Otto Warburg in the 1940s suggested the major role of energetics in cellular function. 139 Although Warburg concentrated on cancer, the relationship of energy starvation of neuronal cells could not have been conceived at that time -unless one read the work of Ramó n y Cajal from the beginning of the 20th century.
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Neurons have comparatively diminished capacity for regeneration and little room for movement. Their placement (wiring?) is critical to their function, and their ability to transmit connecting information is dependent on their intracellular dynamics, powered by mitochondria. 130 Neurons are also quite heterogeneous. 140 Once located in the brain map they primarily undergo slow dendritic branching to form plastic interneuronal connections, a function requiring energy. This general understanding required a few decades of neuroscience research to formulate. There are also many scientists who have made a link between mitochondria and AD through metabolic studies, analyses of mitochondrial DNA for associated mutations, or functional studies of mitochondrial transport in neurons. 33, 121, 124, 127, [141] [142] [143] [144] [145] [146] [147] [148] [149] Most of the elements are, as usual, already somewhere in the literature. Yet none of these mitochondrial dysfunction papers or reviews linked the genetic susceptibility to APOE4 or its C-terminal protein degradation product. 5, 14, 35, 108 Another Nobel laureate, Albert Szent-Gyorgyi, phrased this phenomenon of science as: 'Discovery consists of seeing what everybody has seen and thinking what nobody has thought.' 150 Once the APOE isoform-specific association with AD was known, the decreased utilization of glucose described, and the APOE isoform-specific dependent effect on mitochondrial integrity, a simple picture emerges. Alterations in the integrity, intracellular movement, and functional dynamics could now be appreciated as the triggering process for a cascade of previously defined pathologic phenomena. The first clinical test of the hypothesis, whether increasing mitogenesis with rosiglitazone leads to additional functional neuronal mitochondria, suggests that this hypothesis may prove valuable in discovering new therapies. 5 After the widespread confirmation of the genetic association of APOE4 to AD, a role for apoE4 was sought. For the most part, the research orientation was to try to link one's favored pathologic hypothesis (amyloid, tau, apoptosis, inflammation) to support its connection to the genetic association. In fact, APOE was originally discovered and genotyped as a candidate gene due to its binding to Ab protein from human cerebrospinal fluid in an apoE isoformspecific manner. 9 Similar results were also observed for tau binding, as well as other of the many protein fragments bound into amyloid plaques. [151] [152] [153] [154] However, positron emission tomography (PET), an independent technology that could directly study patients and non-symptomatic subjects, emphasized abnormal glucose utilization as a biomarker in APOE4 carrying subjects (not patients) decades before the other pathological consequences of AD lesions develop. 37, 38, 155 The latest experimental connections demonstrated that apoE is specifically cleaved by a protease in neurons to produce a C-terminal-truncated fragment which affects mitochondrial metabolism and transport within neuronal cells. 58, 108 By damaging mitochondria slowly and progressively throughout life, neurons of APOE4 carriers become dysfunctional earlier than neurons of people who do not inherit APOE4. The protein structure of apoE4 leads to more efficient cleavage with fragments being generated from apoE44apoE34apoE2. 58 This gradient also coincides with the age of onset distributions for AD. [11] [12] [13] The defining structural determinants of apoE4 versus apoE3 are based on the interactions of Arg-61 which is found only in humans and a few high primates. 80, 156 This factor may explain the absence of full AD pathology and progression in rodent models, and the fact that overloading the brain with another associated protein, Ab-amyloid, does not result in the comparable neurodegeneration or brain atrophy. 157 However, it is remarkable that mouse brain glucose utilization is also impaired in mouse models of amyloid overexpression well before Ab deposition takes place. 158 The diagnosis of definite AD is defined by Ab deposition at the time of postmortem examination. [17] [18] [19] [20] PET imagining of Ab during the course of clinical disease will probably show that more amyloid is deposited in neuritic plaques over time, a well-known pathological change with age and APOE genotype. 21 The same could be said for many of the other degradation proteins found in neuritic plaques. Degenerative neurites are also present and may be the template for the various protein depositions. [153] [154] The critical element is what starts first, and it may well be conjecture that the abnormal interactions of apoE4 proteolytic fragments with mitochondria presumably starts with the existence of growing neurons in utero. Certainly, it is present at the earliest ages at which PET scanning can be performed in adults. 159 (PET is not ethically permitted for studies in normal children.) Energy production within the neurons may be adequate for more than half a century, but the differing rates of mitochondrial dysfunction begin to manifest as AD later in life. Even in the diseases inherited as autosomal dominant early-onset AD, the amyloid structure of APP mutations and the abnormal interactions with APP or presenilin mutations may serve as additive complex risk factors to increase the rate of the process. 160 In genetic terms for a complex disease, variants of a number of interacting proteins may serve to enhance the rate and effect of neuronal energy dysfunction.
Virtually all debates regarding theories of AD seem to end on the note that a successful treatment would define the relevance of the science. As there are currently only weak and temporary symptomatic treatments that do not change the progression of the disease, the debates are interminable. Rosiglitazone, while being studied for a possible role in increasing glucose utilization efficiency in AD patients, was also found to increase mitochondrial mRNA transcription quantitatively in an APOE isoform-specific manner in humanized transgenic mice. 35, 138 It was demonstrated that the transcription level per mitochondrion was about the same, but the effect of rosiglitazone was to increase mitogenesis, as was demonstrated previously in adipocytes. 131, 132 Differential clinical improvement in noncarriers of an APOE4 allele during a reasonably sized, dose-ranging clinical trial of rosiglitazone supports these data. 5 Certainly, additional clinical studies will be performed to confirm these initial clinical data in order to meet the criteria for therapeutic registration, but the clinical trial data also support an apoE44apoE34apoE2 mitochondria toxicity hypothesis. Mitochondria damaged by apoE4 may not respond as well as lesser damaged mitochondria. 108 The earlier age of onset distribution in APOE4 homozygotes may represent the absence of lesser damaged mitochondria to respond to needs of dendritic growth or neuronal plasticity.
Efficacy pharmacogenetics based on APOE4-carrier status provided the initial clinical data implicating a mitochondrial substrate for AD disease progression. 5 The neuroscience supports those data. 58 Interactions with other proteins implicated in the pathogenesis of AD can be viewed as the result of energy impairment of the neurons, resulting in stunted, damaged, or dead neurons associated with other pathological protein aggregations. Thus, other susceptibility variants may also affect the process. As the disease progresses, these secondary pathologic manifestations have a catalytic effect on the progression of signs and symptomsa clinical cascade that has been recognized in most of the pathogenic hypotheses. ApoE4 increases the rate of mitochondrial functional impairment, while apoE3 has a lesser effect, supporting a hypothesis involving APOE allelespecific mechanisms in producing differential responses in AD. The epidemiological data suggest that apoE2 protects the brain, but there needs to be additional experimental support for the effect of apoE2 on the brain. 12 In its simplest form, the progression to AD over time can be attributed to differential effects of apoE isoforms on neuronal metabolism starting with decreased glucose utilization in specific regions of the brain. The mitochondria may suffer for decades before symptoms manifest. The progression involves factors which cause associated intraneuronal neurofibrillary changes, decreased neuronal support for maintaining dendritic complexity and plasticity, and recruitment of additional pathologies related to aggregating proteins intimately involved in lipid transport and metabolism -all of which result in what we call 'AD. ' Thus, APOE genotype is essentially a predictive biomarker for the clinical rate of onset, rate of decline, and pathology of AD. 13, 21, 161 From the point of view of clinical trial interpretation, it would not be expected that patients who carry an APOE4 allele leading to a mitotoxic C-terminal degradation factor would necessarily respond as well as patients who do not carry an APOE4 allele. In fact, one might expect that a higher dose of a mitogenic medicine could be necessary for treatment of patients who carry an APOE4 allele. 5 A reasonable clinical/epidemiologic next step to examine these genetic susceptibility differences would be to study patients in the context of age of onset distributions within groups of subjects of the same genotype. 161 The age of onset distributions for each genotype are slightly different. For example, the mean age of onset for APOE4 homozygotes is approximately 15 years earlier than APOE3 homozygotes. 13 APOE genotypes can be used as surrogate biomarkers to predict the rate (age) of onset distribution of AD. A clinical study of asymptomatic subjects in each age group receiving drug or placebo, monitoring for onset of signs and symptoms of AD, could determine whether the medicine delays the age of onset with far fewer patients than would be required if 'all comers' were studied without the APOE biomarker. If the rate of disease onset over time can be demonstrated to be slowed by the drug as a function of APOE genotype, then a mechanism for disease prevention may be suggested for each APOE genotype group. Pharmacogenetic biomarkers are developed to focus clinical trials on smaller, more predictive populations. A similar comparison of the effect of a treatment for T2DM would require smaller numbers of patients if studies were enriched and confined to patients with abnormal glycated hemoglobin (hemoglobin A1C). 162 Larger clinical trials of all comers have a large data-diluting effect. 1, 52, 56 
Conclusion
Pharmacogenetics and disease genetics use the same processes and technologies: the translational medicine example of APOE4, rosiglitazone, and AD.
The previous detailed discussion of the pharmacogenetics of APOE4 status has broader subtle scientific implications. As clinically-classified diseases become characterized for their heterogeneity as they are studied genetically, the responses to medicines (or other external stimuli) can serve as a further basis for 'differences.' While we are familiar with 'steroid-responsive' subdivisions of common diseases, such as asthma, the linking of genetic variation to drug responses is simply a more precise form of diagnosis. Screening for genes associated with disease susceptibility is now an accepted notion, and the scientific field looks forward to the application of genome-wide linkage disequilibrium screening as the next step. 4 PGX has been considered a specialized science, somehow separate from classical 'Mendelian' and complex genetics. In fact there are few differences in the technology, except the experimental laboratory is the world of translational medicine and clinical trials. 56 Academic science and medical centers are struggling to move from the individual scientist's capabilities and a university's interest to an integrated capability for translational medicine and drug development. 163, 164 Luckily, society already has a functional model for developing medicines: pharmaceutical companies.
Both genetic epidemiology of disease and PGX are based on defined abnormal phenotypes: the first as a more obvious function of inheritance and a generally unspecified or perhaps even irrelevant environment; the second as a result of an environmental factor (the drug) interacting with a generally unknown inheritance and a generally unknown environment. The scientific basis of both is about phenotype: history, physical examination and laboratory documentation -actually excellent clinical medicine. The technologies applied for determining the susceptibility genes for a clinically defined disease and the methods used for PGX analyses are generally the same. 165 In science, when there are competing and compelling pathogenic theories, if drug trials based on one of those hypotheses are successful then there is considerable evidence supporting that hypothesis. When a drug demonstrates clinical efficacy, a preliminary (needing confirmation) medical milestone has been achieved. In the case of APOE4 and AD, validation of a pathogenic hypothesis has resulted in an initial step of clinical efficacy -treatment with rosiglitazone. Obviously, this hypothesis will be thoroughly investigated in clinical trials over the next few years. In modern medicine, pathogenic hypotheses are expected to be validated by successful treatment. Much remains to be studied concerning the role of APOE isoforms in neuronal metabolism, but an avenue has been opened for other related investigations in AD as well as in multiple other human degenerative and environmental (including traumatic) diseases.
Finally, it must be clearly emphasized once again that these initial clinical trial data need to be validated in larger registration trials. These data should not change the current recommendations for therapeutic management of AD.
